Joseph Konowiecki, vice chairman and recently chairman, sold 25,000 shares on June 26.
The sale represented 2.2% of Mr. Konowiecki’s direct holdings.
All shares were disposed of from direct ownership; no indirect entities or derivative activity involved.
This transaction matches Mr. Konowiecki’s established pattern of regular, similarly sized open-market sales, reflecting ongoing portfolio management in the context of shrinking capacity.
The current vice chairman, and past chairman, of the board of technology-driven Medicare Advantage provider Alignment Healthcare (NASDAQ:ALHC) sold 25,000 shares on June 26, according to a SEC Form 4 filing.
Joseph S. Konowiecki disclosed the sale of 25,000 shares of common stock in an open-market transaction that netted the executive $575,000.
| Metric | Value |
|---|---|
| Shares sold (direct) | 25,000 |
| Transaction value | $575,000 |
| Post-transaction shares (direct) | 1,128,816 |
| Post-transaction value (direct ownership) | $26.18 million |
Transaction value based on SEC Form 4 reported price ($23.00); post-transaction value based on June 26, 2026 market close ($23.19).
| Metric | Value |
|---|---|
| Price (as of market close June 26, 2026) | $23.00 |
| Market capitalization | $4.90 billion |
| Revenue (TTM) | $4.26 billion |
| 1-year price change | 66.14% |
* 1-year performance calculated using June 26, 2026 as the reference date.
Alignment Healthcare is a leading Medicare Advantage provider focused on technology-enabled, consumer-centric healthcare solutions. The company leverages its proprietary platform to deliver personalized care and efficient plan administration, driving growth across select U.S. markets. Its scale and integrated approach position it to compete effectively in the evolving healthcare landscape.
There are multiple reasons an insider may sell shares of a business. Not all of them signal a bearish outlook for a company’s shares.
But in this case, investors should take notice of Konowiecki’s selling. The executive just stepped down as chairman of the board in June, taking the vice chairman and executive vice president of corporate affairs roles. He and other executives have been steady sellers of the company stock in the past year. While Konowiecki’s sale is part of a trading plan filed in March, investors should be aware that executives are not obligated to sell under such plans — they can cancel the sale as long as they are not doing so on inside information.
Konowiecki received $100,000 in cash for his service on the board last year, in addition to stock awards, and he also serves as CEO of Advanced Sports Media Group.
In short, it’s bearish that Konowiecki is selling, even if the executive still holds 1.2 million shares in the business. Investors should balance this data point with other aspects of Alignment Healthcare to decide whether to invest or continue holding shares. Studies have shown that insider sales are predictive of stock price declines less than half the time.
Before you buy stock in Alignment Healthcare, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alignment Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,890!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,196,664!*
Now, it’s worth noting Stock Advisor’s total average return is 902% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 30, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.